company background image
RENX logo

Renalytix AIM:RENX Stock Report

Last Price

UK£0.095

Market Cap

UK£31.5m

7D

0%

1Y

-32.1%

Updated

19 Dec, 2024

Data

Company Financials

Renalytix Plc

AIM:RENX Stock Report

Market Cap: UK£31.5m

RENX Stock Overview

Develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. More details

RENX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Negative shareholders equity

Earnings have declined by 25.3% per year over past 5 years

Does not have a meaningful market cap (£31M)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Renalytix Plc Competitors

Intelligent Ultrasound Group

AIM:IUG

UK£41.1m

Cambridge Cognition Holdings

AIM:COG

UK£12.7m

Optima Health

AIM:OPT

UK£130.5m

Induction Healthcare Group

AIM:INHC

UK£8.4m

Price History & Performance

Summary of share price highs, lows and changes for Renalytix
Historical stock prices
Current Share PriceUK£0.095
52 Week HighUK£0.75
52 Week LowUK£0.065
Beta2.03
1 Month Change22.58%
3 Month Change2.70%
1 Year Change-32.14%
3 Year Change-98.42%
5 Year Change-97.39%
Change since IPO-92.08%

Recent News & Updates

Recent updates

Shareholder Returns

RENXGB Healthcare ServicesGB Market
7D0%-6.9%-1.5%
1Y-32.1%13.3%3.5%

Return vs Industry: RENX underperformed the UK Healthcare Services industry which returned 13.3% over the past year.

Return vs Market: RENX underperformed the UK Market which returned 3.5% over the past year.

Price Volatility

Is RENX's price volatile compared to industry and market?
RENX volatility
RENX Average Weekly Movement7.4%
Healthcare Services Industry Average Movement5.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: RENX's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: RENX's weekly volatility has decreased from 36% to 7% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2018n/aJames McCulloughrenalytix.com

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix Plc Fundamentals Summary

How do Renalytix's earnings and revenue compare to its market cap?
RENX fundamental statistics
Market capUK£31.46m
Earnings (TTM)-UK£22.37m
Revenue (TTM)UK£1.88m

16.8x

P/S Ratio

-1.4x

P/E Ratio

Is RENX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RENX income statement (TTM)
RevenueUS$2.35m
Cost of RevenueUS$2.05m
Gross ProfitUS$299.00k
Other ExpensesUS$28.33m
Earnings-US$28.03m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.085
Gross Margin12.71%
Net Profit Margin-1,191.75%
Debt/Equity Ratio-72.8%

How did RENX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:34
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Renalytix Plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Mark MassaroBTIG
David WestenbergGuggenheim Securities, LLC